Stock INCY INCYTE CORPORATION
Add to a list
To use this feature you must be a member
Log inSign up

Financials Incyte Corporation

Equities

INCY

US45337C1027

Pharmaceuticals

Market Closed - Nasdaq
Other stock markets
 01:30:00 27/04/2024 am IST 		5-day change 1st Jan Change
51.68 USD +0.98% Intraday chart for Incyte Corporation -1.28% -17.69%
24/04 Oppenheimer Adjusts Incyte Price Target to $84 From $92, Maintains Outperform Rating MT
23/04 Transcript : Escient Pharmaceuticals, Inc., Incyte Corporation - M&A Call

Valuation

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Capitalization 1 18,808 19,048 16,213 17,869 14,072 11,604 - -
Enterprise Value (EV) 1 16,742 17,535 13,865 14,630 10,416 7,231 5,927 4,365
P/E ratio 42.6 x -64 x 17.2 x 52.8 x 23.7 x 15.1 x 11.9 x 9.75 x
Yield - - - - - - - -
Capitalization / Revenue 8.71 x 7.14 x 5.43 x 5.26 x 3.81 x 2.81 x 2.53 x 2.29 x
EV / Revenue 7.76 x 6.58 x 4.64 x 4.31 x 2.82 x 1.75 x 1.29 x 0.86 x
EV / EBITDA 36.7 x -82.8 x 21.5 x 24.5 x 14.8 x 6.93 x 4.37 x 2.51 x
EV / FCF 26.5 x -56.2 x 24.4 x 16.4 x 22.4 x 7.96 x 5.3 x 3.2 x
FCF Yield 3.78% -1.78% 4.1% 6.1% 4.45% 12.6% 18.9% 31.3%
Price to Book 7.22 x 7.26 x 4.32 x 4.09 x 2.71 x 1.83 x 1.52 x 1.26 x
Nbr of stocks (in thousands) 2,15,397 2,18,996 2,20,891 2,22,475 2,24,109 2,24,526 - -
Reference price 2 87.32 86.98 73.40 80.32 62.79 51.68 51.68 51.68
Announcement Date 13/02/20 09/02/21 08/02/22 07/02/23 13/02/24 - - -
1USD in Million2USD
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Net sales 1 2,159 2,667 2,986 3,395 3,696 4,127 4,590 5,058
EBITDA 1 456.5 -211.9 643.6 597.7 703.2 1,043 1,355 1,738
EBIT 1 402 -263.7 585.8 579.4 620.5 1,120 1,444 1,763
Operating Margin 18.62% -9.89% 19.62% 17.07% 16.79% 27.13% 31.45% 34.85%
Earnings before Tax (EBT) 1 486.8 -232.2 570.4 529.1 834.2 1,064 1,320 1,712
Net income 1 446.9 -295.7 948.6 340.7 597.6 797.2 990.6 1,220
Net margin 20.7% -11.09% 31.76% 10.04% 16.17% 19.31% 21.58% 24.13%
EPS 2 2.050 -1.360 4.270 1.520 2.650 3.418 4.329 5.301
Free Cash Flow 1 632.6 -312 568.5 892.1 464 908.6 1,118 1,366
FCF margin 29.3% -11.7% 19.04% 26.28% 12.56% 22.02% 24.35% 27.01%
FCF Conversion (EBITDA) 138.56% - 88.33% 149.27% 65.99% 87.14% 82.47% 78.58%
FCF Conversion (Net income) 141.55% - 59.93% 261.88% 77.64% 113.99% 112.82% 111.93%
Dividend per Share 2 - - - - - - - -
Announcement Date 13/02/20 09/02/21 08/02/22 07/02/23 13/02/24 - - -
1USD in Million2USD
Estimates

Income Statement Evolution (Quarterly data)

Fiscal Period: December 2021 Q3 2021 Q4 2022 Q1 2022 Q2 2022 Q3 2022 Q4 2023 Q1 2023 Q2 2023 Q3 2023 Q4 2024 Q1 2024 Q2 2024 Q3 2024 Q4 2025 Q1
Net sales 1 813 862.9 733.2 911.4 823.3 926.7 808.7 954.6 919 1,013 927.7 1,025 1,052 1,111 1,087
EBITDA 1 250.1 125.6 - 270.9 155.1 137.9 - 214.1 236.1 - 213 313 327 309 -
EBIT 1 235.4 110.7 116.5 254.4 138.4 70.09 24.77 193.8 214.7 187.3 208.5 293.5 316.1 314.3 356.1
Operating Margin 28.96% 12.83% 15.89% 27.92% 16.81% 7.56% 3.06% 20.3% 23.36% 18.48% 22.47% 28.64% 30.05% 28.29% 32.75%
Earnings before Tax (EBT) 1 209.5 120 70.54 229.4 148.6 80.62 51.86 277.6 233.8 271 197.9 283.8 287.7 331.3 -
Net income 1 181.7 563.9 37.99 161.4 112.8 28.46 21.7 203.5 171.3 201.1 131.6 200.2 209.4 236.1 -
Net margin 22.35% 65.35% 5.18% 17.71% 13.7% 3.07% 2.68% 21.32% 18.64% 19.84% 14.19% 19.53% 19.9% 21.25% -
EPS 2 0.8200 2.540 0.1700 0.7200 0.5000 0.1300 0.1000 0.9000 0.7600 0.8900 0.5902 0.8685 0.8818 0.9416 -
Dividend per Share - - - - - - - - - - - - - - -
Announcement Date 02/11/21 08/02/22 03/05/22 02/08/22 01/11/22 07/02/23 02/05/23 01/08/23 31/10/23 13/02/24 - - - - -
1USD in Million2USD
Estimates

Balance Sheet Analysis

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Net Debt 1 - - - - - - - -
Net Cash position 1 2,067 1,513 2,348 3,239 3,656 4,373 5,677 7,239
Leverage (Debt/EBITDA) - - - - - - - -
Free Cash Flow 1 633 -312 568 892 464 909 1,118 1,366
ROE (net income / shareholders' equity) 27.2% -11.4% 29.7% 8.37% 12.5% 17% 18.2% 18.8%
ROA (Net income/ Total Assets) 20.3% -8.46% 22.3% 6.32% 9.47% 14.7% 14.8% 14.9%
Assets 1 2,205 3,494 4,247 5,387 6,312 5,408 6,674 8,177
Book Value Per Share 2 12.10 12.00 17.00 19.60 23.10 28.20 34.00 41.20
Cash Flow per Share 2 3.270 -0.5700 3.370 4.330 2.200 4.400 4.720 -
Capex 1 78.1 187 181 77.8 32.5 140 123 142
Capex / Sales 3.62% 7.03% 6.06% 2.29% 0.88% 3.39% 2.67% 2.8%
Announcement Date 13/02/20 09/02/21 08/02/22 07/02/23 13/02/24 - - -
1USD in Million2USD
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Year-on-year evolution of the Yield

Change in Enterprise Value/EBITDA

Ratings for Incyte Corporation

Trading Rating
Investor Rating
ESG Refinitiv
B-
More Ratings

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
24
Last Close Price
51.68 USD
Average target price
75.2 USD
Spread / Average Target
+45.51%
Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Biopharmaceuticals

1st Jan change Capi.
INCYTE CORPORATION Stock Incyte Corporation
-17.69% 11.6B
CSL LIMITED Stock CSL Limited
-4.66% 86.13B
SAMSUNG BIOLOGICS CO.,LTD. Stock Samsung Biologics Co.,Ltd.
+1.32% 39.82B
BIOGEN INC. Stock Biogen Inc.
-19.27% 30.42B
UCB Stock UCB
+57.86% 25.23B
CHONGQING ZHIFEI BIOLOGICAL PRODUCTS CO., LTD. Stock Chongqing Zhifei Biological Products Co., Ltd.
-43.00% 11.51B
BEIJING WANTAI BIOLOGICAL PHARMACY ENTERPRISE CO., LTD. Stock Beijing Wantai Biological Pharmacy Enterprise Co., Ltd.
-9.14% 11.95B
SWEDISH ORPHAN BIOVITRUM AB Stock Swedish Orphan Biovitrum AB
+5.24% 8.71B
INNOVENT BIOLOGICS, INC. Stock Innovent Biologics, Inc.
-8.42% 8.12B
INTRA-CELLULAR THERAPIES, INC. Stock Intra-Cellular Therapies, Inc.
+2.29% 7.72B
Biopharmaceuticals
  1. Stock Market
  2. Equities
  3. INCY Stock
  4. Financials Incyte Corporation